Invention Grant
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/docs/US/2020-06-02/US10669269B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
-
Application No.: US15717700Application Date: 2017-09-27
-
Publication No.: US10669269B2Publication Date: 2020-06-02
- Inventor: Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsäter , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
- Applicant: ARRAY BIOPHARMA INC.
- Applicant Address: US CO Boulder
- Assignee: Array BioPharma Inc.
- Current Assignee: Array BioPharma Inc.
- Current Assignee Address: US CO Boulder
- Agency: Viksnins Harris Padys Malen LLP
- Main IPC: A61K31/496
- IPC: A61K31/496 ; A61K45/06 ; C07D471/04
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/abs-image/US/2020/06/02/US10669269B2/abs.jpg.150x150.jpg)
Abstract:
Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Public/Granted literature
Information query
IPC分类:
